Hemolytic disease of the fetus and newborn: epidemiology, antibody profile, and clinical outcomes from universal direct antiglobulin test screening. A retrospective study from Saudi Arabia
Background HDFN is a significant cause of newborn mortality. This study aimed to identify the frequency of primary alloantibodies responsible for HDFN and evaluate associated clinical outcomes at a tertiary care hospital in Riyadh, Saudi Arabia. Methods This retrospective study analyzed 4,340 newborns. Direct antiglobulin test (DAT)-positive cases were evaluated. Lui freeze-thaw elution and acid elution procedures were used to detect specific ABO and Rh incompatibilities, respectively. Lui freeze-thaw elution was used for ABO antibody detection due to the labile nature of anti-A/anti-B binding, while acid elution was used for Rh and other non-ABO antibodies due to its higher sensitivity for IgG-mediated sensitization. Clinical outcomes including hyperbilirubinemia, Neonatal Intensive Care Unit (NICU) admission, and red blood cell (RBC) transfusions were evaluated. Results Out of 4,340 newborns, 267 (6.1%) tested DAT-positive. Among these, ABO incompatibility was the most frequent finding (76%, n = 204), primarily blood type B antibodies ( n = 106). Suspected Rh incompatibility accounted for 23.5% ( n = 63), with confirmed Rh antibody-mediated cases comprising 54 (20.2%) of the DAT-positive cohort; anti-D was the most frequent antibody ( n = 28). The remaining nine cases (3.4%) were classified as suspected Rh incompatibility with negative eluate. Clinically significant non-ABO antibodies, including anti-E ( n = 7) and anti-c ( n = 5), were also identified. Hyperbilirubinemia was the main clinical complication, affecting 44% of the DAT-positive cohort. The background rate of hyperbilirubinemia in the DAT-negative cohort was not systematically extractable; therefore, the clinical significance of the 44% rate cannot be fully determined and should be interpreted with caution. Despite this, clinical outcomes were generally mild: 61% of infants did not require NICU admission, and only 4.1% of DAT-positive newborns ( n = 11) required RBC transfusions. Conclusion ABO incompatibility was the main cause of HDFN at KFMC, generally resulting in favorable clinical outcomes. Future studies should evaluate whether a maternal-targeted selective DAT screening strategy, paired with comprehensive prenatal antibody profiling, could optimize resources while maintaining safety. However, this is a hypothesis-generating proposition based on our single-center data; direct comparative studies evaluating universal vs. selective screening strategies are needed before any policy changes are implemented. Future multi-center studies are recommended to confirm these findings in the Kingdom.
Authors
- Ammar Hasan Alsughayir (ORCID: https://orcid.org/0000-0003-3606-0542)
- Alyazeed S. Alsaif
- Muhammad Raihan Sajid (ORCID: https://orcid.org/0000-0002-6082-3928)
- Mohammed Khalid Alkhalifah (ORCID: https://orcid.org/0000-0003-2112-6318)
- Salman Aldosari
- Sarah Bakr Abobakr (ORCID: https://orcid.org/0000-0002-0981-9894)
- Rasha M. Khayata
- Jana H. Husein
- Yazeed Abdullah Alfalah
- Sara Alkahwaji
- Haifa Alhowaidi
Institutions
- Alfaisal University (SA)
- Qassim University (SA)
- King Fahd Medical City (SA)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3389/fmed.2026.1921820
- Primary Topic
- Blood groups and transfusion
- Type
- article
- Field-Weighted Citation Impact
- 0.00